157 related articles for article (PubMed ID: 34041707)
21. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe.
Davenport C; Gravel P; Wang Y; Williams SA; Wieland A; Mitlak B
Ther Innov Regul Sci; 2024 May; 58(3):505-518. PubMed ID: 38341388
[TBL] [Abstract][Full Text] [Related]
22. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
[TBL] [Abstract][Full Text] [Related]
23. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
[TBL] [Abstract][Full Text] [Related]
24. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
Hartmann M; Mayer-Nicolai C; Pfaff O
Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
[TBL] [Abstract][Full Text] [Related]
25. An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe.
Ebbers HC; Langedijk J; Bouvy JC; Hoekman J; Boon WP; de Jong JP; De Bruin ML
Eur J Clin Pharmacol; 2015 Oct; 71(10):1237-44. PubMed ID: 26204969
[TBL] [Abstract][Full Text] [Related]
26. Licensing failure in the European decentralised procedure.
Langedijk J; Ebbers HC; Mantel-Teeuwisse AK; Kruger-Peters AG; Leufkens HG
Eur J Pharm Sci; 2016 May; 87():47-51. PubMed ID: 26493584
[TBL] [Abstract][Full Text] [Related]
27. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
28. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
29. Requirements on efficacy of herbal medicinal products.
Claeson P
J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782
[TBL] [Abstract][Full Text] [Related]
30. [European Agency for the Evaluation of Medicinal Products: five years experience].
Sauer F
Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
[TBL] [Abstract][Full Text] [Related]
31. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
32. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ.
Borg JJ; Laslop A; Pani L; Maciulaitis R; Melchiorri D
Sci Pharm; 2014; 82(3):541-54. PubMed ID: 25853067
[TBL] [Abstract][Full Text] [Related]
33. Approvals of drugs with uncertain benefit-risk profiles in Europe.
Banzi R; Gerardi C; Bertele' V; Garattini S
Eur J Intern Med; 2015 Oct; 26(8):572-84. PubMed ID: 26342723
[TBL] [Abstract][Full Text] [Related]
34. Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.
Refalo N; Chetcuti D; Tanti A; Serracino-Inglott A; Borg JJ
Saudi Pharm J; 2017 Feb; 25(2):280-289. PubMed ID: 28344480
[TBL] [Abstract][Full Text] [Related]
35. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
[TBL] [Abstract][Full Text] [Related]
36. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
[TBL] [Abstract][Full Text] [Related]
37. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
38. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rosian K; Wild C; Simon J
Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
[TBL] [Abstract][Full Text] [Related]
39. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
[TBL] [Abstract][Full Text] [Related]
40. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.
Mulder J; Verjans R; Verbaanderd C; Pean E; Weemers J; Leufkens HGM; Pignatti F; de Boer A; Voest EE; Stoyanova-Beninska VV; Pasmooij AMG
Front Med (Lausanne); 2021; 8():790782. PubMed ID: 34957158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]